VANCOUVER, British Columbia, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed that its licensee, Spectrum Pharmaceuticals, Inc. (Nasdaq:SPPI), announced that it has launched Marqibo through its existing hematology sales force in the United States and has shipped the first commercial orders. Tekmira is entitled to royalty payments based on Marqibo’s commercial sales.
Help employers find you! Check out all the jobs and post your resume.